TVTX
Travere Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Travere Therapeutics (TVTX) Stock: Buy, Sell, or Hold?
$52.16
+0.12 (+0.23%)
▲
5d:
+6.73%
30d:
-2.08%
90d:
-16.06%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 02, 2026
0d
Protect TVTX Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (72%)
Quality Score
57/100
Position
FAIR
30-Day Fair Range
$49.66 – $54.35
Position: FAIR
Forward P/E & Valuation
9.6x
CHEAP
vs 11.5x historical avg
Wall Street Target
$73.43
+41.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$44.73 / $53.30
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: TVTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When TVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$121.32
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$75.33
30.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TVTX is currently trading at $52.16, which is considered fair relative to its 30-day fair value range of $49.66 to $54.35. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.6) compared to its historical average (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TVTX is in a strong uptrend. The price is approaching resistance at $53.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $73.43 (+41.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TVTX is in a strong uptrend. The price is approaching resistance at $53.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $73.43 (+41.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$49.66 -
$54.35
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
Trading Range & Key Levels
30-Day Trading Range
$49.66 -
$54.35
Current vs Trading Range
FAIR
Support Level
$44.73
Resistance Level
$53.30
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding TVTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.1% below Wall St target ($73.43)
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Fundamental Context
Forward P/E (Next Year Est.)
9.61
Wall Street Target
$73.43
(+41.1%)
Revenue Growth (YoY)
36.2%
Profit Margin
-18.7%
Valuation Discount vs History
-5.8% cheaper
PE vs Historical
9.6 vs 11.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.8%
(market-implied from PE analysis)
1-Year Target
$49.02
(-6%)
2-Year Target
$46.18
(-11%)
3-Year Target
$43.50
(-16%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$52.08
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 914.9%)
$363.12
(+598%)
Base:
(SPY PE: 9.6, Growth: 914.9%)
$175.63
(+238%)
Bear:
(PE: 8.2, Growth: 914.9%)
$149.29
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.6 to 11.5
Stabilization Target:
$62.30
(+19.7%)
PE Expansion Potential:
+19.7%
Share TVTX Analysis
Share this live TVTX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (TVTX)
Bearish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 3, 2026
Daily AI digest
AI Retail Discussion Summary:
Travere Therapeutics reported Q3 loss that beat revenue estimates but missed EPS estimates, causing bearish sentiment on StockTwits.
Key Retail Themes:
earnings report
revenue and EPS estimates
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 50 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$64 | 48 HOLD |
Advanced TVTX Option Strategies
Professional options setups generated by AI based on today's TVTX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive TVTX Research Pages
